LYRA Stock Analysis: Buy, Sell, or Hold?
LYRA - Lyra Therapeutics, Inc. Common Stock
$0.50
-0.83 (-62.50%)
▼
5d:
-61.92%
30d:
-62.5%
90d:
-87.62%
WAIT
LOW Confidence
Analysis Updated: Mar 16, 2026 12:00 AM ET
Earnings: Mar 12, 2026
0d
Get Alerted When LYRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LYRA is down 61.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LYRA is down 61.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYRA is currently trading at $0.49, which is considered fair based on recent price action.
Technical Outlook: Technically, LYRA is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 62.5% recently.
Market Sentiment: LYRA scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.00 (+3132.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYRA is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 62.5% recently.
Market Sentiment: LYRA scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.00 (+3132.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
44/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
76.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BEARISH: Downward momentum (-62.5%)
- BULLISH: Trading 3132.3% below Wall St target ($16.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.42
Current Trend
Strong Downtrend
Technical data as of
Mar 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.07
Wall Street Target
$16.00
(+3132.3%)
Revenue Growth (YoY)
-87.2%
Share & Embed Analysis
Last updated: August 09, 2026 1:12 AM ET
Data refreshes hourly during market hours. Next update: 2:12 AM
Data refreshes hourly during market hours. Next update: 2:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 63 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 54 HOLD |
